Literature DB >> 18931337

Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues.

Aldrin V Gomes1, Glen W Young, Yueju Wang, Chenggong Zong, Mansoureh Eghbali, Oliver Drews, Haojie Lu, Enrico Stefani, Peipei Ping.   

Abstract

The 20 S proteasome complexes are major contributors to the intracellular protein degradation machinery in mammalian cells. Systematic administration of proteasome inhibitors to combat disease (e.g. cancer) has resulted in positive outcomes as well as adversary effects. The latter was attributed to, at least in part, a lack of understanding in the organ-specific responses to inhibitors and the potential diversity of proteomes of these complexes in different tissues. Accordingly, we conducted a proteomic study to characterize the 20 S proteasome complexes and their postulated organ-specific responses in the heart and liver. The cardiac and hepatic 20 S proteasomes were isolated from the same mouse strain with identical genetic background. We examined the molecular composition, complex assembly, post-translational modifications and associating partners of these proteasome complexes. Our results revealed an organ-specific molecular organization of the 20 S proteasomes with distinguished patterns of post-translational modifications as well as unique complex assembly characteristics. Furthermore, the proteome diversities are concomitant with a functional heterogeneity of the proteolytic patterns exhibited by these two organs. In particular, the heart and liver displayed distinct activity profiles to two proteasome inhibitors, epoxomicin and Z-Pro-Nle-Asp-H. Finally, the heart and liver demonstrated contrasting regulatory mechanisms from the associating partners of these proteasomes. The functional heterogeneity of the mammalian 20 S proteasome complexes underscores the concept of divergent proteomes among organs in the context of an identical genome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931337      PMCID: PMC2634581          DOI: 10.1074/mcp.M800058-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  33 in total

Review 1.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

Authors:  Michael H Glickman; Aaron Ciechanover
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

Review 2.  The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design.

Authors:  A Sijts; D Zaiss; P M Kloetzel
Journal:  Curr Mol Med       Date:  2001-12       Impact factor: 2.222

3.  NEDD8 recruits E2-ubiquitin to SCF E3 ligase.

Authors:  T Kawakami; T Chiba; T Suzuki; K Iwai; K Yamanaka; N Minato; H Suzuki; N Shimbara; Y Hidaka; F Osaka; M Omata; K Tanaka
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

4.  Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1.

Authors:  T Kamitani; K Kito; T Fukuda-Kamitani; E T Yeh
Journal:  J Biol Chem       Date:  2001-10-03       Impact factor: 5.157

5.  High throughput two-dimensional blue-native electrophoresis: a tool for functional proteomics of mitochondria and signaling complexes.

Authors:  Paul S Brookes; Anita Pinner; Anup Ramachandran; Lori Coward; Stephen Barnes; Helen Kim; Victor M Darley-Usmar
Journal:  Proteomics       Date:  2002-08       Impact factor: 3.984

6.  Multiple associated proteins regulate proteasome structure and function.

Authors:  David S Leggett; John Hanna; Anna Borodovsky; Bernat Crosas; Marion Schmidt; Rohan T Baker; Thomas Walz; Hidde Ploegh; Daniel Finley
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

7.  Automated identification of putative methyltransferases from genomic open reading frames.

Authors:  Jonathan E Katz; Mensur Dlakić; Steven Clarke
Journal:  Mol Cell Proteomics       Date:  2003-07-18       Impact factor: 5.911

8.  Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.

Authors:  Abdullah Hacihanefioglu; Pinar Tarkun; Emel Gonullu
Journal:  Int J Hematol       Date:  2008-07-17       Impact factor: 2.490

9.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Authors:  Christos N Papandreou; Danai D Daliani; Darrell Nix; Hong Yang; Timothy Madden; Xuemei Wang; Christine S Pien; Randall E Millikan; Shi-Ming Tu; Lance Pagliaro; Jeri Kim; Julian Adams; Peter Elliott; Dixie Esseltine; Alexandria Petrusich; Pauline Dieringer; Cherie Perez; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  Regulated interaction between polypeptide chain elongation factor-1 complex with the 26S proteasome during Xenopus oocyte maturation.

Authors:  Toshinobu Tokumoto; Ayami Kondo; Junko Miwa; Ryo Horiguchi; Mika Tokumoto; Yoshitaka Nagahama; Noriyuki Okida; Katsutoshi Ishikawa
Journal:  BMC Biochem       Date:  2003-07-16       Impact factor: 4.059

View more
  46 in total

Review 1.  Post-translational modification of cardiac proteasomes: functional delineation enabled by proteomics.

Authors:  Sarah B Scruggs; Nobel C Zong; Ding Wang; Enrico Stefani; Peipei Ping
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-20       Impact factor: 4.733

2.  Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.

Authors:  Benoît Guillaume; Jacques Chapiro; Vincent Stroobant; Didier Colau; Benoît Van Holle; Grégory Parvizi; Marie-Pierre Bousquet-Dubouch; Ivan Théate; Nicolas Parmentier; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

Review 3.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

4.  Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.

Authors:  Jie Li; Saul R Powell; Xuejun Wang
Journal:  FASEB J       Date:  2010-11-23       Impact factor: 5.191

5.  Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure.

Authors:  Viswanathan Rajagopalan; Mingming Zhao; Sushma Reddy; Giovanni Fajardo; Xuejun Wang; Shannamar Dewey; Aldrin V Gomes; Daniel Bernstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-31       Impact factor: 4.733

Review 6.  Proteasome inhibitors and cardiac cell growth.

Authors:  Nadia Hedhli; Christophe Depre
Journal:  Cardiovasc Res       Date:  2009-07-03       Impact factor: 10.787

7.  Impaired methylation as a novel mechanism for proteasome suppression in liver cells.

Authors:  Natalia A Osna; Ronda L White; Terrence M Donohue; Michael R Beard; Dean J Tuma; Kusum K Kharbanda
Journal:  Biochem Biophys Res Commun       Date:  2009-12-21       Impact factor: 3.575

Review 8.  Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil.

Authors:  Hanming Zhang; Xuejun Wang
Journal:  Future Cardiol       Date:  2015-03

Review 9.  The ubiquitin proteasome system and myocardial ischemia.

Authors:  Justine Calise; Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-07       Impact factor: 4.733

10.  Clarifying the cardiac proteasome paradox: protein quality control.

Authors:  Christopher C Glembotski
Journal:  Circ Res       Date:  2012-08-17       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.